Background. Complications related to the diagnosis and treatment of Trichomonas vaginalis infection, as well as the association between T. vaginalis infection and increased transmission of and susceptibility to human immunodeficiency virus, highlight the need for alternative interventions. We tested a human-safe, aluminum hydroxideadjuvanted whole-cell T. vaginalis vaccine for efficacy in a BALB/c mouse model of vaginal infection.
Trichomonas vaginalis is the most common nonviral sexually transmitted pathogen [1] . Recent estimates from 2008 reported an incidence of 276 million and prevalence of 187 million T. vaginalis infections, increases of 11.5% and 22.2%, respectively, from estimates in 2005 [1, 2] . Since the majority of T. vaginalis infections are asymptomatic in men and women, these statistics likely underestimate the actual global burden of disease [1, 3] . Typical symptoms for men include pain and inflammation of the urogenital tract. Moreimportant sequelae are infertility, benign prostatic hyperplasia, and prostate cancer [3] [4] [5] [6] [7] [8] . Because of the large burden of asymptomatic disease, particularly in males, the pathogenic potential of T. vaginalis is underrecognized. Infections in females include symptoms such as vaginal discharge, increased vaginal pH, inflammation of the reproductive tract, and itching, and untreated infection leads to chronic infection. Sequelae of greater concern include infertility, cervical cancer, pelvic inflammatory disease, and adverse events with implications for fetal and newborn health, including preterm labor, premature rupture of membranes, and low birth weight [4, [9] [10] [11] [12] [13] [14] . Trichomonas vaginalis infection is also correlated with increased susceptibility to and transmission of human immunodeficiency virus (HIV) [4] .
The causal relationship between HIV susceptibility and transmission and T. vaginalis infection is unclear. Modes of HIV acquisition due to T. vaginalis infection have been speculated to be due to damage to the vaginal epithelial layer caused by inflammation, increased monocytic cell susceptibility to HIV, and bacterial vaginosis or changes in vaginal flora colonization [15] [16] [17] [18] . Epidemiological studies report increased susceptibility to HIV when an individual is already infected with T. vaginalis (odds ratio, 1.52-2.74) [19] [20] [21] . Increased transmission of HIV may be due to a higher level of viral shedding into the genital tract or to genital ulcers [22, 23] . Finally, higher rates of T. vaginalis and HIV coinfection were found in pregnant women, compared with nonpregnant women (P < .05), which can increase the risk of vertical transmission of HIV [24] . A model used to estimate coinfections in the United States used an odds ratio of 1.8 and attributed 2% of all HIV infections to T. vaginalis infections [17] . However, this value likely underestimates the attribution of T. vaginalis infections, owing to the prevalence of asymptomatic diseases and underdiagnosis.
Previously, we developed a mouse vaginal infection model of T. vaginalis and showed the potential of vaccination to prevent disease and reduce the duration of infection [25] . This model used Freund adjuvant. Although T. vaginalis infection is curable in most cases with imidazole agents, resistance to imidazole has increased, and T. vaginalis is often unrecognized and infection undiagnosed, especially in low-resource countries. Thus, preventing infection by delivery of an affordable vaccine could have a major impact on maternal-child health and reduce HIV transmission. To address this need, we studied a T. vaginalis vaccine that contains a human-appropriate adjuvant, aluminum hydroxide (alum), in our mouse vaginal infection model. We assessed the effect of vaccination, relative to that of no vaccination, on the initial number and duration of T. vaginalis infections, the levels of T. vaginalis-specific immunoglobulin present in serum and the local vaginal environment, and the presence of CD4 + and CD8 + T cells in vaginal tissue. Immunological data were recorded before and after infection and with and without vaccination, to assess changes in the immunological response over time.
METHODS

Vaccination
Mice were vaccinated 8 weeks (day −56) and 4 weeks (day −28) before vaginal infection (day 0). The vaccine consisted of 1 × 10 6 whole-cell T. vaginalis in Freund complete/incomplete adjuvant (hereafter, "Freund"), 0.50 mg of alum (hereafter, "alum 0.50 mg"), or 0.75 mg of alum (hereafter, "alum 0.75"). A sham vaccination group was included that received 0.75 mg of alum without whole-cell T. vaginalis (hereafter, "alum sham"). Unvaccinated mice acted as controls. Inoculum regimen and key procedure dates followed previously establish protocols [25] in our laboratory (Supplementary Table 1 ).
Animals and Animal Care
Female BALB/c mice weighing 17-19 g were obtained from Charles River (Charles River Laboratories, Montreal, Canada), housed in the animal care facilities at the University of Ottawa Roger Guindon Campus (Ottawa, Canada) in groups of 4, and randomly allocated to receive vaccine, sham vaccine, or no vaccine. All procedures performed on mice were approved by the Animal Care Committee of the University of Ottawa, Faculty of Medicine, for ethical consideration, (protocol number BMI-108).
Blood Collection
Blood specimens were collected from the saphenous vein 3 weeks after the prime vaccination (day −33), 3 weeks after the boost vaccination (day −7), and 2 and 4 weeks following intravaginal challenge with T. vaginalis. Blood samples were stored at room temperature for 2 hours and then centrifuged for 20 minutes at 2000g. Serum was pipetted from the collection tubes into microtubes and stored at −80°C.
Vaginal Washes
Infection status was determined on days 7, 14, and 28 after vaginal infection, by culture of vaginal washes. Culture tubes were incubated at 37°C in 5% CO 2 and assessed for growth after 4 days.
We assessed presence of T. vaginalis-specific total immunoglobulin G (IgG) from vaginal washes, which were performed on days 1, 3, 7, 14, 21, and 28 following intravaginal challenge with T. vaginalis. In brief, 50 µL of phosphate-buffered saline (PBS) was pipetted gently and repeatedly up to 10 times in the vagina of mice. The liquid was aspirated and transferred to a microfuge tube containing 1 µL of a protease inhibitor cocktail (P8340, Sigma-Aldrich, St. Louis, Missouri). An additional wash was repeated for a final volume of 100 µL. This volume was centrifuged at 12 000g for 10 minutes at 4°C. The supernatant was extracted and replaced with an additional 100 µL of fresh PBS with 1 µL of protease inhibitor cocktail and then rotated in an incubator at 20 rpm (orbit diameter 1.27 cm) for 2 hours at 4°C. Extraction was repeated for a final 300-µL volume and stored at −20°C.
Enzyme-Linked Immunosorbent Assays (ELISAs)
A laboratory preparation of T. vaginalis (OC15) lysate was coated overnight at 4°C on 96-well, high-binding cell culture plates (Costar 3595; Corning, New York) at a concentration of 2 µg/mL OC15 lysate in a total volume of 50 µL. The wash step consisted of the following: wells were emptied, washed 3 times with PBS-T wash buffer (PBS plus 0.005% Tween 20), and dried. One hundred microliters of blocking buffer (PBS-T plus 1% bovine serum albumin [BSA]) were added to each well. Following incubation of blocking buffer, plates were washed. For serum samples, the wells were then filled with 100 µL of PBS-T with 0.1% BSA and 0.5 µL of undiluted serum. For vaginal wash samples, 40 µL of PBS-T with 0.1% BSA and 60 µL of vaginal wash extract were added to each well. The plates were incubated for 2 hours at room temperature and then washed. Peroxidase-conjugated goat anti-mouse monoclonal antibodies (Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania) were added in a total volume of 100 µL of PBS-T to each well at the following dilutions: 1:10 000 IgG, 1:5000 IgG 2a , and 1:7000 IgG 1 . The plates were incubated for 2 hours at room temperature and then washed. Urea buffered o-phenylenediamine (Sigma-Aldrich) was added to each well at a total volume of 100 µL. Serum ELISA plates were incubated for 25 minutes at room temperature and then read at 450 nm on a Biorad Microplate Reader (model no. 3550; Hercules, California). For vaginal wash ELISA plates, a stopping solution consisting of 25 µL of 3 M HCl was added to each well after incubation for 25 minutes at room temperature. These plates were read at 490 nm. IgG-positive serum, IgGnegative serum, and blank wells were controls.
Immunohistochemical Analysis
Vaginas were harvested from mice euthanized on days −1, 1, 3, 7, 14, 21, and 28. Tissues were embedded in Tissue-Tek OCT (Sakura Finetek, Torrance, California) by flash freezing. Serial duplicate vaginal tissues cut 7-µm thick across the lumen at −19°C by using a microtome were thawed onto Superfrost Plus Gold microscope slides (catalog no. 22-035813; Fisher Scientific, Ottawa, Canada) and stored at −80°C.
Tissues were dried and fixed with acetone. Next, the tissues were rehydrated in Tris-buffered saline (TBS; pH 7.6) for 10 minutes. TBS was decanted, and tissues were incubated for 10-20 minutes at room temperature with 1% BSA in TBS as a suppressor. Excess suppressor was decanted, and diluted rat anti-mouse primary antibodies in TBS were added for detection of either CD4 + T cells 
RESULTS
Effect of Vaccination on Vaginal Infection
Unvaccinated mice had significantly more infections on day 7, compared with mice in the Freund and alum groups (P < .005). Pooled results are from 5 separate experiments (Table 1) . Vaccine efficacy, calculated on the basis of infections on day 7, was 64%, 61%, and 72% for the Freund, alum 0.50, and alum 0.75 groups, respectively. The number of T. vaginalis infections in the unvaccinated group on day 28 was also significantly greater than that in the vaccinated groups (P < .005). A total of 100%, 63%, 75%, and 23% of infections detected on day 7 were cleared by day 28 in the Freund, alum 0.50, alum 0.75, and unvaccinated groups, respectively. Vaccinated mice had fewer initial infections on day 7 after vaginal infection and greater clearance of initial infections by day 28 after vaginal infection, compared with unvaccinated mice. By day 28, the percentages of mice with vaginal infection were 0% in the Freund group, 12% in the alum 0.50 group, 6% in the alum 0.75 group, 20% in the alum sham group, and 61% in the unvaccinated group.
Serum and Vaginal Immunoglobulin Levels
Mice immunized with adjuvant and trichomonads had significantly higher serum levels of total IgG and IgG 1 (P < .05) at all time points, compared with mice in the unvaccinated and alum sham groups (Figure 1 ). High serum levels of total IgG and IgG 1 were maintained 28 days following intravaginal T. vaginalis challenge in the Freund, alum 0.50, and alum 0.75 groups. Total IgG and IgG 1 detection was nearly absent at each time point for the unvaccinated and alum sham groups. Serum IgG 2a responses were not detected in the unvaccinated or alum sham groups but could be detected in some mice from the Freund, alum 0.50, and alum 0.75 groups (Supplementary Figure 1) . The IgG 2a response in the Freund group was significantly greater (P < .05) than that in the alum 0.75, alum sham, and unvaccinated groups 3 weeks after receipt of the boost vaccination. The IgG 2a response in the Freund group was significantly greater (P < .05) than that in the alum sham and unvaccinated groups 4 weeks after infection. The cumulative effect of subcutaneous immunization of mice with adjuvant and T. vaginalis antigen was a pronounced total IgG and IgG 1 response with variable IgG 2a production. Vaginal IgG was detected almost exclusively in vaccinated mice (Figure 2 and Supplementary Figure 2) .
Immunohistochemical Detection of CD4
+ and CD8 + T Cells in
Vaginal Tissues
Immunohistochemical staining was performed on vaginal tissue to the investigate cell-mediated immune response in the vaginal tissues (Table 2 and Figure 3) . Distribution of cells in 
DISCUSSION
Trichomonas vaginalis infection in humans and experimental animal models does not result in protection against reinfection [25, 26] . Indeed, reinfection is often seen in those at high risk of reexposure to T. vaginalis, including sex workers, people who engage in risky sexual behaviors, and women whose sex partner has not been treated for T. vaginalis infection [27] [28] [29] [30] . Additional infections can be attributed to a lack of adherence to treatment, as well as to treatment failure [31, 32] . Repeat and untreated T. vaginalis infections are particularly problematic in pregnant women because of the risk of adverse pregnancy outcomes and the increased susceptibility to infection with and transmission of HIV [4, 12, 19, 33] .
A vaccine would be particularly ideal for preventing the asymptomatic carriers, who are reservoirs of T. vaginalis infection. Vaccination against the bovine trichomoniasis, Tritrichomonas foetus, has been successful in preventing infections in young bulls and reducing the duration of infection in heifers. The vaccine results in greater pregnancy rates and successful births, and it produces preputial, vaginal, uterine, and systemic IgG 1 , IgG 2 , and immunoglobulin A anti-trichomonad antibody responses [34] [35] [36] [37] [38] .
This study used the same animal model and vaccination procedures as Abraham et al [25] , except for our use of an adjuvant formulation safe for human vaccination. Since the use of Freund adjuvant is not safe for human applications, we aimed to evaluate a vaccine formulation with an adjuvant that is approved as safe for humans. Using the OC15 T. vaginalis isolate, derived from a symptomatic patient, we produced a simple whole-cell vaccine with two different concentrations of aluminum from a premade aluminum hydroxide adjuvant (Alhydrogel). The alum vaccines (alum 0.50 and alum 0.75) and the Freund vaccine had significantly fewer initial infections measured on day 7 after intravaginal challenge with T. vaginalis, compared with unvaccinated mice (P < .005).
Alum contact with dendritic cells (DCs) stimulates an increase of ICAM-1 and LFA-1, which are CD4 + T-cell adhesion molecules, and has an antigen-nonspecific function [39] . If either the primed DCs or alum crystals can migrate to vaginal tissues, then the DCs in vaginal tissue could have tighter associations to present T. vaginalis antigen for the first time, compared with unvaccinated mice. This could explain the unexpected low numbers of initial infections and clearance of infection in the alum sham group, compared with the unvaccinated group. Nevertheless, vaccinated mice were significantly protected from infection on day 7 after infection, compared with nonvaccinated mice, and were more likely to clear infection by day 28.
The presence of anti-trichomonal immunoglobulin during infection has been documented in humans [40] . The role of immunoglobulin remains unclear because virulence factors of T. vaginalis are capable of degrading immunoglobulin [41] and may prevent complement activation or antibody-dependent cell-mediated cytotoxicity [42] . To our knowledge, epitope specificity of antibodies in humans has not been investigated and could be another potential reason for ineffective natural and anamnestic immune responses in humans. Although immunoglobulin is detected during an active vaginal infection in humans, its presence does not seem to afford protection during or after infection. Perhaps immunoglobulin levels during natural infection are ineffective, but immunoglobulin levels achieved after vaccination may be protective, suggesting that the mode of antigen presentation has a differential effect on protection.
Overall, the local and systemic immunoglobulin results we report coincide with the report by Abraham et al [25] that immunoglobulin responses are detected at higher levels in serum after vaccination, compared with findings for controls, and that levels are particularly high after vaginal infection. Also, vaginal IgG is more likely to be detected in vaccinated mice, compared with controls, following vaginal infection. Alum vaccination was as effective at producing serum and vaginal immunoglobulin responses as Freund vaccination. This shows that the viability of a human-adapted T. vaginalis vaccine is a possibility for future protection studies.
The detection of a local humoral immune response could suggest locally produced antibodies or antibodies arising from systemic circulation. Other innate or adaptive immune mediators may be at play to influence clearance of infection, since not all mice that cleared infection had vaginal immunoglobulin levels above the cutoff.
Paintlia et al [43] isolated lymphocytes from vaginal cervical tissue obtained from mice challenged with a symptomatic isolate, those challenged with an asymptomatic isolate, or those not challenged (uninfected control). The process to isolate lymphocytes uses enzymes and dissociation medium to release lymphocytes from the excised tissues. However, peripheral blood lymphocyte contamination is a concern owing to the presence of small blood vessels, which cannot be excised prior to To overcome these methodological issues, we performed immunohistochemical analyses on a mouse vaginal infection model. This histological approach gives a more definite idea of where and how many lymphocytes are located within the tissue. Also, immunohistochemical assessment of the impact of vaccination on the presence of lymphocytes following a T. vaginalis infection has not been reported. We used an immunohistochemical staining procedure to investigate frozen vaginal samples obtained at various time points after infection from vaccinated and unvaccinated mice. There was a lack of CD4 + T cells in specimens obtained before infection, regardless of vaccine status. After infection, we found CD4 + T cells in tissue specimens from at least half of the mice in the vaccinated and the alum sham groups but in specimens from 33% of mice in the unvaccinated group. With the small number of samples tested at various time points, we could not determine the kinetics of the CD4 + T-cell presence after infection or after clearance of infection because the vaginal infection is not uniformly distributed, and it is possible to miss areas of T-cell infiltration or presence. However, it is clear that T. vaginalis induces a CD4 + T-cell presence in vaginal tissue. This effect has potential implications on the transmission and acquisition of HIV. CD4 + T cells were more likely to be detected in vaccinated mice and in greater numbers within the vaginal tissue. Mice in the alum and alum sham groups had a reduction in CD4 + T cells after 2 weeks after infection. The alum vaccine efficacy was 61%-72%. Furthermore, 63%-75% of infections on day 7 were cleared by day 28 among mice in the alum groups, compared with unvaccinated mice, among which only 23% cleared Thus, the attraction of an affordable T. vaginalis vaccine that can impact maternal-child health by reducing T. vaginalis and that may reduce HIV transmission and acquisition merits serious future consideration.
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